Oklahoma Children's Memorial Hospital at the University of Oklahoma is a member institution of the Pediatric Oncology Group. We have pooled our patient resources and scientific expertise to study the natural history of childhood cancer, develop effective therapeutic regimens, and evaluate the toxicity and effectiveness of new anti-cancer agents in the treatment of childhood cancer. The program is also characterized by a number of non-therapeutic protocols that are evaluating tumor biology. The team at the University of Oklahoma is multidisciplinary and includes pediatric hematologists/oncologists, radiation therapists, radiologists, pediatric surgeons, immunologists, and pathologists. All protocols are reviewed by the Institutional Review Board prior to activation and informed consent is obtained on all patients entered into protocols of the Pediatric Oncology Group. The core program in Oklahoma City has a close collaborative relationship with the two-year clinical College of Medicine in Tulsa, Oklahoma and the University of Arizona is an affiliate of our program in Oklahoma. Protocol compliance has remained a high priority. Our one-year, short-term and our long-term (1 to 3 years) compliance are 91 and 94%, respectively and both are above the group average. Research interests at the University of Oklahoma include, not only evaluation of tumor biology and therapeutic protocols, but also an evaluation of informed consent. We have completed a six-year evaluation of informed consent, published our findings, and are currently planning a phase II protocol. We serve as a reference laboratory with regard to immune phenotypes of the cells of histocytosis X.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Oklahoma Health Sciences Center
Schools of Medicine
Oklahoma City
United States
Zip Code
Gilbert, M Melissa; Tipping, Marla; Veraksa, Alexey et al. (2011) A screen for conditional growth suppressor genes identifies the Drosophila homolog of HD-PTP as a regulator of the oncoprotein Yorkie. Dev Cell 20:700-12
Wacker, Pierre; Land, Vita J; Camitta, Bruce M et al. (2007) Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study. J Pediatr Hematol Oncol 29:627-32
Chintharlapalli, Sudhakar; Papineni, Sabitha; Jutooru, Indira et al. (2007) Structure-dependent activity of glycyrrhetinic acid derivatives as peroxisome proliferator-activated receptor {gamma} agonists in colon cancer cells. Mol Cancer Ther 6:1588-98
Chintharlapalli, Sudhakar; Papineni, Sabitha; Baek, Seung Joon et al. (2005) 1,1-Bis(3'-indolyl)-1-(p-substitutedphenyl)methanes are peroxisome proliferator-activated receptor gamma agonists but decrease HCT-116 colon cancer cell survival through receptor-independent activation of early growth response-1 and nonsteroidal anti-infl Mol Pharmacol 68:1782-92
Ravindranath, Y; Chang, M; Steuber, C P et al. (2005) Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia 19:2101-16
Shamberger, Robert C; LaQuaglia, Michael P; Gebhardt, Mark C et al. (2003) Ewing sarcoma/primitive neuroectodermal tumor of the chest wall: impact of initial versus delayed resection on tumor margins, survival, and use of radiation therapy. Ann Surg 238:563-7; discussion 567-8
Goorin, Allen M; Schwartzentruber, Douglas J; Devidas, Meenakshi et al. (2003) Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 21:1574-80
Lacayo, N J; Lum, B L; Becton, D L et al. (2002) Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia. Leukemia 16:920-7
Laver, Joseph H; Mahmoud, Hazem; Pick, Terry E et al. (2002) Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non-Hodgkin's lymphoma: a Pediatric Oncology Group study. Leuk Lymphoma 43:105-9
Bell, B A; Chang, M N; Weinstein, H J (2001) A phase II study of Homoharringtonine for the treatment of children with refractory or recurrent acute myelogenous leukemia: a pediatric oncology group study. Med Pediatr Oncol 37:103-7

Showing the most recent 10 out of 31 publications